Anebulo Pharmaceuticals Files 2024 Annual Report

TL;DR

ANEB filed its 2024 10-K, met all filing requirements. Check financials for details.

AI Summary

Anebulo Pharmaceuticals, Inc. filed its annual report for the fiscal year ended June 30, 2024. The company is registered in Delaware and its common stock trades under the ticker ANEB on the Nasdaq Stock Market LLC. The filing indicates that Anebulo Pharmaceuticals, Inc. has met its filing requirements for the preceding 12 months and the past 90 days, and has submitted all required Interactive Data Files.

Why It Matters

This 10-K filing provides a comprehensive overview of Anebulo Pharmaceuticals' financial health and operational status for the fiscal year ending June 30, 2024, which is crucial for investors to assess the company's performance and future prospects.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Anebulo Pharmaceuticals is subject to inherent risks related to drug development, regulatory approvals, and market competition, which are detailed within the full 10-K filing.

Key Players & Entities

• Anebulo Pharmaceuticals, Inc. (company) — Registrant
• June 30, 2024 (date) — Fiscal year end
• Delaware (jurisdiction) — State of incorporation
• 85-1170950 (identifier) — I.R.S. Employer Identification No.
• 1017 Ranch Road 620 South , Suite 107 Lakeway , Texas 78734 (address) — Principal executive offices
• (512) 598-0931 (phone_number) — Registrant's telephone number
• Common Stock (security) — Registered security
• ANEB (ticker) — Trading Symbol
• Nasdaq Stock Market LLC (exchange) — Exchange where registered

FAQ

Key Financial Figures

• $0.9 million — 4, we were awarded the first tranche of $0.9 million of a two-year cooperative grant of up t
• $1.9 million — grant of up to a total of approximately $1.9 million from the National Institute on Drug Abu

Filing Documents

• form10-k.htm (10-K) — 1854KB
• ex19-1.htm (EX-19.1) — 38KB
• ex23-1.htm (EX-23.1) — 5KB
• ex31-1.htm (EX-31.1) — 13KB
• ex31-2.htm (EX-31.2) — 10KB
• ex32-1.htm (EX-32.1) — 7KB
• ex32-2.htm (EX-32.2) — 7KB
• ex97-1.htm (EX-97.1) — 5KB
• form10-k_001.jpg (GRAPHIC) — 263KB
• form10-k_002.jpg (GRAPHIC) — 373KB
• form10-k_004.jpg (GRAPHIC) — 226KB
• ex97-1_001.jpg (GRAPHIC) — 1217KB
• ex97-1_002.jpg (GRAPHIC) — 1638KB
• ex97-1_003.jpg (GRAPHIC) — 1661KB
• ex97-1_004.jpg (GRAPHIC) — 1546KB
• ex97-1_005.jpg (GRAPHIC) — 477KB
• 0001493152-24-038127.txt ( ) — 16463KB
• aneb-20240630.xsd (EX-101.SCH) — 25KB
• aneb-20240630_cal.xml (EX-101.CAL) — 38KB
• aneb-20240630_def.xml (EX-101.DEF) — 98KB
• aneb-20240630_lab.xml (EX-101.LAB) — 266KB
• aneb-20240630_pre.xml (EX-101.PRE) — 221KB
• form10-k_htm.xml (XML) — 492KB

Disclosure Regarding Foreign Jurisdictions that Prevents Inspections

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevents Inspections 72 PART III 72

Directors, Executive Officers and Corporate Governance

Item 10. Directors, Executive Officers and Corporate Governance 72

Executive Compensation

Item 11. Executive Compensation 77

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 89

Certain Relationships and Related Transactions, and Director Independence

Item 13. Certain Relationships and Related Transactions, and Director Independence 91

Principal Accounting Fees and Services

Item 14. Principal Accounting Fees and Services 93 PART IV 94

Exhibits and Financial Statement Schedules

Item 15. Exhibits and Financial Statement Schedules 94

Form 10-K Summary

Item 16. Form 10-K Summary 95 In this Annual Report on Form 10-K (this "Annual Report"), unless otherwise stated or as the context otherwise requires, references to "Anebulo Pharmaceuticals," "Anebulo," "the Company," "we," "us," "our" and similar references refer to Anebulo Pharmaceuticals, Inc. The Anebulo logo, and other trademarks or service marks of Anebulo Pharmaceuticals, Inc. appearing in this Annual Report are the property of Anebulo Pharmaceuticals, Inc. This Annual Report also contains registered marks, trademarks and trade names of other companies. All other trademarks, registered marks and trade names appearing in this Annual Report are the property of their respective holders. We do not intend our use or display of other companies' trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, these other companies. 2 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), which are subject the "safe harbor" created by those sections. These forward-looking statements about us and our industry involve substantial risks and uncertainties and our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth below under Part I, Item 1A, "Risk Factors" in this Annual Report. All statements other than statements of historical facts contained in this Annual Report, including statements regarding our future financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking "may," "could," "will," "estimate," "continue,"

Risk Factors

Risk Factors We are required to establish and maintain effective internal control over financial reporting. We have increased costs as a public company and our management is required to devote time to compliance. Changes in accounting principles or guidance could result in unfavorable accounting charges or effects. Reduced disclosure requirements for emerging growth companies, may make our securities less attractive. Changes in tax laws or regulations may have a material adverse effect on our business. Our ability to use net operating loss carryforwards and certain other tax attributes may be limited. If analysts do not publish favorable reports about us, our stock price and trading volume could decline. Health epidemics or pandemics may adversely affect our financial condition and results of operations. Unstable market and economic conditions, geopolitical conditions, and other factors beyond our control may have serious adverse consequences on our business, financial condition and stock price. Inflation may adversely affect us by increasing our costs. Our actual or perceived failure to comply with policies and other obligations related to data privacy and security could lead to regulatory investigations or actions and other adverse business consequences. If our internal information technology systems or sensitive information, or those of our third-party contractors or consultants, are or were compromised, we could experience adverse consequences. We cannot assure you that our common stock will remain listed on the Nasdaq Capital Market. 4 We have not generated any revenue since our inception and expect to incur future losses and may never become profitable. Our business is highly dependent on our lead product candidate, selonabant (formerly ANEB-001), and we must complete clinical testing before we can seek regulatory approval and begin commercialization of any of our product candidates We depend substantially on intellectual prop

View Full Filing

View this 10-K filing on SEC EDGAR